
---
title: '新冠疫苗混合接种效果可能更好！'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761139'
author: 科学网
comments: false
date: Fri, 06 Aug 2021 08:24:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761139'
---

<div>   
<p style="text-autospace:ideograph-numeric;line-height:200%"><a name="OLE_LINK1" href="http://blog.sciencenet.cn/undefined"></a>      <strong style="text-indent: 73px;"><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 32px;background: #FFFFFF">新冠疫苗混合接种效果可能更好！</span></strong></p><p style="text-indent: 73px; line-height: 200%;"><strong style="text-indent: 67px;"><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF">德国汉诺</span></strong><strong style="text-indent: 67px;"><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF">威</span></strong><strong style="text-indent: 67px;"><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF">（</span></strong><strong style="text-indent: 67px;"><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF">Hannover</span></strong><strong style="text-indent: 67px;"><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF">）</span></strong><strong style="text-indent: 67px;"><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF">医学院</span></strong><strong style="text-indent: 67px;"><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF">的研究人员</span></strong><strong style="text-indent: 67px;"><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF">7月14日在《</span></strong><span style="color: #FF0000;"><strong style="text-indent: 67px;"><span style="font-family: KaiTi; line-height: 200%; letter-spacing: 0px; font-size: 29px; background: #FFFFFF;">Nat</span></strong><strong style="text-indent: 67px;"><span style="font-family: KaiTi; line-height: 200%; letter-spacing: 0px; font-size: 29px; background: #FFFFFF;">ure </span></strong><strong style="text-indent: 67px;"><span style="font-family: KaiTi; line-height: 200%; letter-spacing: 0px; font-size: 29px; background: #FFFFFF;">Med</span></strong><strong style="text-indent: 67px;"><span style="font-family: KaiTi; line-height: 200%; letter-spacing: 0px; font-size: 29px; background: #FFFFFF;">icine</span></strong></span><strong style="text-indent: 67px;"><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF">（自然　医学）》杂志报告了他们的临床试验结果。</span></strong><strong style="text-indent: 67px;"><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF"> </span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">现在获准紧急使用的新冠疫苗有好多种，多数的标准接种程序是同一种疫苗打２针。如果不同种类的新冠疫苗混合使用结果会如何？</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">例如，是否可以将</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">阿斯利康</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">（</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">AstraZeneca</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">）</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">生产的疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">作第一针，而将</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">辉瑞</span>/BioNTech生产的疫苗</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">作为第二针</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">混合使用</span>?</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">最新的科学研究表明，这种疫苗方案实际上比</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">使用</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">两</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">针</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">相同疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">方案</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">能</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">引发更强的免疫反应。</span></span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">60岁以下人群在接受</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">腺病毒载体疫苗</span></span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">(如</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">阿斯利康和强生公司生产的疫苗</span></span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">)后偶尔会发生血栓</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">，这</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">已经促使几个欧洲政府建议仅对</span>60岁以上的人使用这些疫苗。因为60岁以下的很多人已经接种第一</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">针</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">阿斯利康疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">而</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">仍然需要</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">第二</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">针</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">,他们必须决定他们应该继续他们</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">原来</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">的方案</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">即第二针接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">相同的疫苗</span>(即同源方案),</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">还是</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">接</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">一</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"> </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF">mRNA疫苗</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">(即</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">采用异源</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">方案</span>)。</span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761139" title alt="image.png" width="705" height="370" style="width: 705px; height: 370px;" referrerpolicy="no-referrer"> </span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">为了评估一种异</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">源</span></strong><span style="text-decoration: underline;"><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; text-decoration: underline; font-family: KaiTi;">新冠病毒（</span></strong><strong><span style="text-decoration: underline; font-family: KaiTi; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;">SARS-CoV-2</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; text-decoration: underline; font-family: KaiTi;">）</span></strong></span><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">疫苗</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">方案的有效性，德国</span></strong><strong><span style="text-decoration: underline; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">汉诺威</span></strong><strong><span style="text-decoration: underline; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">（</span></strong><strong><span style="text-decoration: underline; font-family: KaiTi; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;">Hannover</span></strong><strong><span style="text-decoration: underline; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">）</span></strong><strong><span style="text-decoration: underline; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">医学院</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">的研究人员</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">7月１４日在《</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF">Nat</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF">ure </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF">Med</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF">icine</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">（自然　医学）》杂志发表一篇简报，报告了他们的相关临床试验结果。</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">该试验旨在监测卫生保健专业人员和可能接触</span>SARS-CoV-2的个人对SARS-CoV-2的免疫反应。所有研究参与者都已经接受了阿斯利康的第一</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">针</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">疫苗</span>(阿斯利康</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">疫苗</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">在</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">本项</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">研究中称为</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF">ChAd</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">)，第二</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">针则可</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">选择接</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">种</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">相同疫苗</span>ChAd</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">，</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">或辉瑞</span>/BioNTech的mRNA疫苗(称为</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF">BNT</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">)。</span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">尽管这两种疫苗都编码</span>SARS-CoV-2全长</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">刺突</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">（</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">spike</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">）</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">蛋白的基因，但其表达方式略有不同。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">在</span>ChAd疫苗中，刺突蛋白编码</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">序列插入</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">黑猩猩来源的腺病毒载体中，而在</span>BNT疫苗中，刺突蛋白</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF">mRNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">序列</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">被脂质纳米颗粒</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">包裹</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">在参与这项研究的</span>87名患者中，32人选择</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">第二</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">针</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">是</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">ChAd，55人选择</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">的是</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">BNT疫苗。选择了相同ChAd/ChAd方案的参与者在第73天接受了第二</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">针</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">ChAd</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">，并在</span>16天后</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">提供</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">了血液样本用于分析。选择异</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">源</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">ChAd/BNT方案的参与者在初始</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">ChAd</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">74天后接</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">BNT</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">，并在</span>17天后</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">提供</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">血液样本。</span></span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">对这两组血液样本的所有分析结果与</span>46名接种了两</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">针</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">BNT(即</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">接种同</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">一种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">的</span>BNT/BNT方案)的保健专业人员的结果进行了比较。</span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF">　　</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:KaiTi">研究</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:KaiTi">的主要</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:KaiTi">结果如下</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:KaiTi">：</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">相对于第一</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">针疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">诱导的抗体水平，</span>ChAd</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">作为</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">同源增强导致抗</span>SARS-CoV-2刺突蛋白的IgG抗体增加了</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF">2.9倍</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">。</span>IgG抗体主要存在于血液中，为抵抗入侵病原体提供大部分基于抗体的免疫。相比之下，BNT的异</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">源</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">增强导致抗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">剌突抗体</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">IgG增加</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF">11.5倍</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">，在</span>BNT/BNT接种个体观察到的范围内。</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">在抗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">剌突</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">IgA抗体中也观察到类似的模式</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">，这种抗体主要存在于粘膜及其液体中。</span> </span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">与</span>ChAd相比，</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">用</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">BNT</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">作第二针</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">增强诱导抗</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">剌突</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">IgA抗体明显增加，表明</span></strong><span style="color: #0070C0;"><strong><span style="font-family: KaiTi; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;">异种增强方案</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">可</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">诱导更好的抗体反应</span></strong></span><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">。</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">有趣的是，尽管加强免疫在两个接种组中都诱导了中和</span>(即病毒灭活)抗体的增加，但</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">只有异源</span>ChAd/BNT疫苗诱导的抗体中和了所有三种测试变体</span></strong><strong><span style="line-height: 200%; color: #FF0000; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">阿尔法、贝塔和伽玛</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 21px;background: #FFFFFF">(Alpha、Beta和Gamma)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">，这与</span>BNT/BNT疫苗接种者中观察到的</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">结果</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">相似。</span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">作者还分析了两种不同的增强方案对</span></strong><strong><span style="text-decoration: underline; font-family: KaiTi; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;"><span style="font-family:KaiTi">刺突特异性记忆</span>B细胞</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">的影响，这些细胞在血液中安静地循环，在随后接触</span>SARS-CoV-2时可以迅速产生刺突特异性抗体。ChAd/ChAd和ChAd/BNT组的所有疫苗接种者在接受加强注射后</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">都</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">产生了更高水平的刺突特异性记忆</span>B细胞，两组之间没有观察到显著差异。这些结果强调了<span style="font-family: KaiTi; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; color: #0070C0;">加强疫苗接种对全面预防SARS-CoV-2感染的重要性。</span></span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">与</span>ChAd/ChAd</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">接种</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">者相比，</span></strong><span style="color: #FF0000;"><strong><span style="font-family: KaiTi; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;">ChAd/BNT</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">接种</span></strong><strong><span style="font-family: KaiTi; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;"><span style="font-family: KaiTi;">者的特异性</span>CD4+和CD8+T细胞水平也显著更高。</span></strong></span><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">CD4+T细胞是适应性免疫反应的核心元素，因为它们</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">可激活</span><a name="OLE_LINK2" href="http://blog.sciencenet.cn/undefined"></a></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">B<span style="font-family:KaiTi">细胞和</span>CD8+T细胞</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">，</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">B</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">细胞可</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">分泌抗体</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">，而</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">CD8+T细胞</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">则可</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">杀死</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">被</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">感染</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">的</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">目标细胞。</span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">与</span>ChAd/ChAd方案相比，ChAd/BNT疫苗也显著增加了产生</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">剌突</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">特异性干扰素</span>γ的T细胞水平，这种细胞因子抑制病毒复制并激活巨噬细胞，</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">而</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">巨噬细胞可吞噬和消化病原体。总的来说，这些结果表明，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:KaiTi">异</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:KaiTi">源</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 24px;background: #FFFFFF">ChAd/BNT方案诱导的免疫应答明显强于同源ChAd/ChAd方案</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 24px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-size: 24px; color: #0070C0;"><strong><span style="font-size: 24px; line-height: 200%; letter-spacing: 0px; background: #FFFFFF; font-family: KaiTi;">这项研究</span></strong><strong><span style="font-size: 24px; line-height: 200%; letter-spacing: 0px; background: #FFFFFF; font-family: KaiTi;">也</span></strong><strong><span style="font-size: 24px; line-height: 200%; letter-spacing: 0px; background: #FFFFFF; font-family: KaiTi;">有几个</span></strong><span style="font-size: 24px; text-decoration: underline;"><strong><span style="font-size: 24px; text-decoration: underline; line-height: 200%; letter-spacing: 0px; background: #FFFFFF; font-family: KaiTi;">局限性</span></strong></span></span><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">。</span></strong><span style="text-decoration: underline; color: #0070C0;"><strong><span style="text-decoration: underline; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">首先</span></strong></span><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">，这不是一个随机的、安慰剂</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">对照</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">的试验，每个参与者</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">并非</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">被随机分配到一个实验组或</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">对照</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">组。随机试验参与者消除了与所分析的变量无关的</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">其他因素</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">的影响，因此实验组和对照组之间唯一的预期差异是</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">所</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">研究的</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">变量引发的</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">结果</span>(本例中的疗效)。对照组的受试者接受安慰剂，安慰剂是一种没有治疗效果的物质，这样人们就可以确定实验组观察到的效果是真实的，是实验药物的结果。</span></strong><span style="text-decoration: underline; color: #0070C0;"><strong><span style="text-decoration: underline; font-family: KaiTi; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;">其次</span></strong></span><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF">，作者未测试这些抗体中和<a name="OLE_LINK3" href="http://blog.sciencenet.cn/undefined"></a></span></strong><strong><span style="text-decoration: underline; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">德尔塔</span></strong><strong><span style="text-decoration: underline; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">（</span></strong><strong><span style="text-decoration: underline; font-family: KaiTi; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;">Delta</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">）</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">变异的能力，德尔塔变异最近在世界许多地区成为主要流</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">行</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">的变异</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">株</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">。</span></strong><span style="text-decoration: underline;"><strong><span style="text-decoration: underline; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi; color: #0070C0;">第三</span></strong></span><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">，该研究主要包括年轻人和健康人群，因此很难将数据外推到该类别之外的其他特定患者群体。</span></strong><span style="text-decoration: underline;"><strong><span style="text-decoration: underline; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi; color: #0070C0;">第四</span></strong></span><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">，这些数据仅显示体外试验的结果，这可能并不一定表现出临床意义。</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">还需要</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">进一步研究</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">以</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF; font-family: KaiTi;">确定观察到的免疫反应的实际重要性，以验证这些反应的相关性。</span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">尽管有局限性，这项研究提供的信息可能具有一些有价值的实际意义。目前批准的大多数</span>SARS-CoV-2疫苗方案涉及同一疫苗的两</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">针</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">。然而，在某些情况下，获得两</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">针</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">相同疫苗的机会可能有限或缺乏，因此</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">有时</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">必须使用不同类型的疫苗来</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">完成</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">第</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">二针</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">加强接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><span style="color: #0070C0;"><strong><span style="font-family: SimSun; line-height: 200%; font-size: 21px;">参考文献：</span></strong></span></p><p style="margin-left: 0px; text-indent: 43px; line-height: 200%;"><span style="font-family: 'Segoe UI';line-height: 200%;color: #222222;letter-spacing: 0;font-size: 19px;background: #FFFFFF">Barros-Martins, J.</span><span style="font-family: 'Segoe UI';line-height: 200%;color: #222222;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> </span><span style="font-family: 'Segoe UI';line-height: 200%;color: #222222;letter-spacing: 0;font-size: 19px;background: #FFFFFF">et al.</span><span style="font-family: 'Segoe UI';line-height: 200%;color: #222222;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> </span><strong><span style="font-family: 'Segoe UI';line-height: 200%;color: #222222;letter-spacing: 0;font-size: 19px;background: #FFFFFF">Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. </span></strong><strong><span style="font-family: 'Segoe UI';line-height: 200%;color: #FF0000;letter-spacing: 0;font-size: 19px;background: #FFFFFF">Nat Med </span></strong><span style="font-family: 'Segoe UI';line-height: 200%;color: #222222;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(2021). </span><a href="https://doi.org/10.1038/s41591-021-01449-9" target="_blank"><span style="text-decoration:underline;"><span style="font-family: 'Segoe UI';line-height: 200%;color: #0000FF;letter-spacing: 0;font-size: 19px;background: #FFFFFF">https://doi.org/10.1038/s41591-021-01449-9</span></span></a><span style="font-family: SimSun;line-height: 200%;color: #222222;letter-spacing: 0;font-size: 19px;background: #FFFFFF">　</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-347754-1298561.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-347754-1298561.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1298235.html" target="_black">学术专著《狂犬病和狂犬病疫苗》中文译稿链接</a><br>下一篇：<a href="http://blog.sciencenet.cn/blog-347754-1298760.html" target="_black">未来的新冠疫苗将如何发展？</a>                    <!--大赛结束-->
                                        
  
</div>
            